Don L. Siegel

Comparison of intestinal histopathological changes following teclistamab, BCMA ‐directed CAR T, CD19 ‐directed CAR T and rituximab therapies

Aims Immunotherapy‐associated intestinal tract injury is increasingly recognized; however, histological patterns associated with specific agents remain incompletely defined. Data directly comparing CD19‐ and BCMA‐directed CAR T therapies with other B‐cell‐targeted treatments are...